Fraiser Kansteiner
About Fraiser Kansteiner
Fraiser Kansteiner is a reporter known for his contributions to pharmaceutical journalism, including articles on gene therapy and drug exclusivity.
Fraiser Kansteiner Reporter Profile
Fraiser Kansteiner is a reporter known for contributing insightful articles on various healthcare and pharmaceutical topics. His work is recognized for detailed analysis and factual reporting. As a journalist, Fraiser has focused on significant developments in the medical field, covering news that impacts both professionals and the general public. His articles often provide comprehensive coverage of new drug approvals, acquisitions, and market exclusivity changes.
Fraiser Kansteiner Article on Orchard's FDA Approval for MLD Gene Therapy
On March 18, 2024, Fraiser Kansteiner authored an article titled 'After Kyowa Kirin buyout, Orchard scores FDA approval for first MLD gene therapy in the US.' The article discusses the significant milestone for Orchard Therapeutics as it received FDA approval for its gene therapy to treat Metachromatic Leukodystrophy (MLD). This approval came after Kyowa Kirin's acquisition of Orchard, highlighting the impact of corporate strategies on medical advancements.
Co-authored Article on US Drug Exclusivity Losses in 2024
Fraiser Kansteiner co-authored an article with Eric Sagonowsky, Zoey Becker, Angus Liu, and Kevin Dunleavy titled 'The top 10 drugs losing US exclusivity in 2024,' published on March 11, 2024. This article provides a comprehensive list of drugs that are set to lose their market exclusivity in the US within the year. It offers detailed insights into the implications of these changes for the pharmaceutical industry and healthcare providers, as well as potential impacts on drug pricing and availability.